Mitochondrial medicine: to a new era of gene therapy for mitochondrial DNA mutations
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Mitochondrial disorders can no longer be ignored in most medical disciplines. Such disorders include specific and widespread organ involvement, with tissue degeneration or tumor formation. Primary or secondary actors, mitochondrial dysfunctions also play a role in the aging process. Despite progresses made in identification of their molecular bases, nearly everything remains to be done as regards therapy. Research dealing with mitochondrial physiology and pathology has >20 years of history around the world. We are involved, as are many other laboratories, in the challenge of finding ways to fight these diseases. However, our main limitation is the scarcety of animal models required for both understanding the molecular mechanisms underlying the diseases and evaluating therapeutic strategies. This is especially true for diseases due to mutations in mitochondrial DNA (mtDNA), since an authentic genetic model of mtDNA mutations is technically a very difficult task due to both the inability of manipulating the mitochondrial genome of living mammalian cells and to its multicopy nature. This has led researchers in the field to consider the prospect of gene therapy approaches that can roughly be divided into three groups: (1) import of wild‐type copies or relevant sections of DNA or RNA into mitochondria, (2) manipulation of mitochondrial genetic content, and (3) rescue of a defect by expression of an engineered gene product from the nucleus (allotopic or xenotropic expression). We briefly introduce these concepts and indicate where promising progress has been made in the last decade.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145 · cited 3×
“It is tremendously encouraging to see that gene replacement therapy for RPE65 driven by recombinant adeno-associated virus (rAAV2) was safe and effective, even in adults who had severely advanced disease (Bainbridge et al. 2008; Maguire et al. 2008; Cideciyan et al. 2008; Cideciyan et al. 2009b; Maguire et al. 2009).”
BackgroundThe Role of Mitochondria in Apoptosis
Wang, C., & Youle, R. J. (2009) · Annual Review of Genetics · doi:10.1146/annurev-genet-102108-134850 · Cited by 1,987
Effect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924 · cited 4×
“It is tremendously encouraging to see that gene replacement therapy for RPE65 driven by recombinant adeno-associated virus (rAAV2) was safe and effective, even in adults who had severely advanced disease (Bainbridge et al. 2008; Maguire et al. 2008; Cideciyan et al. 2008; Cideciyan et al. 2009b; Maguire et al. 2009).”
BackgroundInfluentialFunction and biogenesis of iron-sulphur proteins
Lill, R. (2009) · Nature · doi:10.1038/nature08301 · Cited by 1,167
Kaplitt, M. G., Feigin, A., Tang, C., Fitzsimons, H. L., Mattis, P., Lawlor, P. A., Bland, R. J., Young, D., Strybing, K., Eidelberg, D., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60982-9 · Cited by 1,067
Maguire, A. M., High, K. A., Auricchio, A., Wright, J. F., Pierce, E. A., Testa, F., Mingozzi, F., Bennicelli, J. L., Ying, G.-S., Rossi, S., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61836-5 · Cited by 865 · cited 3×
“It is tremendously encouraging to see that gene replacement therapy for RPE65 driven by recombinant adeno-associated virus (rAAV2) was safe and effective, even in adults who had severely advanced disease (Bainbridge et al. 2008; Maguire et al. 2008; Cideciyan et al. 2008; Cideciyan et al. 2009b; Maguire et al. 2009).”
BackgroundGeneration of transgenic non-human primates with germline transmission
Sasaki, E., Suemizu, H., Shimada, A., Hanazawa, K., Oiwa, R., Kamioka, M., Tomioka, I., Sotomaru, Y., Hirakawa, R., Eto, T., et al. (2009) · Nature · doi:10.1038/nature08090 · Cited by 712
Somatic mtDNA mutations cause aging phenotypes without affecting reactive oxygen species production
Trifunovic, A., Hansson, A., Wredenberg, A., Rovio, A. T., Dufour, E., Khvorostov, I., Spelbrink, J. N., Wibom, R., Jacobs, H. T., & Larsson, N.-G. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508886102 · Cited by 555
A mouse model of mitochondrial disease reveals germline selection against severe mtDNA mutations
Fan, W., Waymire, K. G., Narula, N., Li, P., Rocher, C., Coskun, P. E., Vannan, M. A., Narula, J., MacGregor, G. R., & Wallace, D. C. (2008) · Science · doi:10.1126/science.1147786 · Cited by 466
Davies, V. J., Hollins, A. J., Piechota, M. J., Yip, W., Davies, J. R., White, K. E., Nicols, P. P., Boulton, M. E., & Votruba, M. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddm079 · Cited by 449 · cited 2×
“2007), (Davies et al. 2007).”
MethodWorgall, S., Sondhi, D., Hackett, N. R., Kosofsky, B., Kekatpure, M. V., Neyzi, N., Dyke, J. P., Ballon, D., Heier, L., Greenwald, B. M., et al. (2008) · Human Gene Therapy · doi:10.1089/hum.2008.022 · Cited by 402 · cited 3×
“Ultimately, along with ongoing clinical trials on late infantile neuronal ceroid lipofuscinosis (LINCL) (Worgall et al. 2008) and PD (Kaplitt et al. 2007), (Feigin et al. 2007), they will likely lead to major breakthroughs for neurodegenerative diseases in general and mitochondrial illness in…”
BackgroundA role for mitochondrial enzymes in inherited neoplasia and beyond
Eng, C., Kiuru, M., Fernandez, M. J., & Aaltonen, L. A. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1013 · Cited by 392
Selective inhibition of mutant human mitochondrial DNA replication in vitro by peptide nucleic acids
Taylor, R. W., Chinnery, P. F., Turnbull, D. M., & Lightowlers, R. N. (1997) · Nature Genetics · doi:10.1038/ng0297-212 · Cited by 249 · cited 2×
“…sections of DNA or RNA into mitochondria either to replace mutant tRNA (Kolesnikova et al. 2004) or to selectively inhibit mutant mtDNA replication (Taylor et al. 1997) (Taylor et al. , 2000); (2) manipulation of the mitochondrial genetic content by importing specific restriction endonucleases…”
BackgroundKolesnikova, O. A., Entelis, N. S., Jacquin-Becker, C., Goltzene, F., Chrzanowska-Lightowlers, Z. M., Lightowlers, R. N., Martin, R. P., & Tarassov, I. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh267 · Cited by 157
Role of dichloroacetate in the treatment of genetic mitochondrial diseases
Stacpoole, P. W., Kurtz, T. L., Han, Z., & Langaee, T. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.02.014 · Cited by 145 · cited 1×
“Three of them maintained normal venous blood lactate levels and stable clinical conditions; one 16-year-old girl experienced some behavioral instability, and another 12-year-old girl was withdrawn from DCA because of worsening peripheral nerve conduction (Stacpoole et al. 2008).”
BackgroundBonnet, C., Augustin, S., Ellouze, S., Bénit, P., Bouaita, A., Rustin, P., Sahel, J.-A., & Corral-Debrinski, M. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2008.04.018 · Cited by 130 · cited 3×
“…that cut mutated but not wild-type mtDNA (Bacman et al. 2007); and (3) rescue a defect by expression of an engineered gene product from the nucleus (allotopic or xenotropic expression) to replace mutated mtDNA genes or to complement faulty function (Bonnet et al. 2008), (Dassa et al. 2009).”
BackgroundSelf-citationProtection by the NDI1 gene against neurodegeneration in a rotenone rat model of Parkinson's disease
Marella, M., Seo, B. B., Nakamaru-Ogiso, E., Greenamyre, J. T., Matsuno-Yagi, A., & Yagi, T. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001433 · Cited by 116 · cited 1×
“The presence of the Ndi1 protein also protected against cell death and oxidative damage (Marella et al. 2008).”
BackgroundBonnet, C., Kaltimbacher, V., Ellouze, S., Augustin, S., Bénit, P., Forster, V., Rustin, P., Sahel, J.-A., & Corral-Debrinski, M. (2007) · Rejuvenation Research · doi:10.1089/rej.2006.0526 · Cited by 98 · cited 2×
“We obtained a complete and durable rescue of OXPHOS dysfunction in fibroblasts from patients bearing deleterious mutations in ATP6, ND1, and ND4 genes (Bonnet et al. 2007), (Bonnet et al.”
BackgroundSelf-citationProgress and prospects: gene therapy for mitochondrial DNA disease
Kyriakouli, D. S., Boesch, P., Taylor, R. W., & Lightowlers, R. N. (2008) · Gene Therapy · doi:10.1038/gt.2008.91 · Cited by 76 · cited 3×
“must be done to determine whether they can inhibit mtDNA replication in whole cells and be delivered to defective mitochondria in animals (Kyriakouli et al. 2008).”
Background
Cited by
Gene Therapy for Leber Hereditary Optic Neuropathy
Feuer, W. J., Schiffman, J. C., Davis, J. L., Porciatti, V., Gonzalez, P., Koilkonda, R. D., Yuan, H., Lalwani, A., Lam, B. L., & Guy, J. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2015.10.025 · Cited by 230
Cwerman-Thibault, H., Augustin, S., Ellouze, S., Sahel, J.-A., & Corral-Debrinski, M. (2014) · Comptes Rendus. Biologies · doi:10.1016/j.crvi.2013.11.011 · Cited by 49
Self-citationStable nuclear expression of ATP8 and ATP6 genes rescues a mtDNA Complex V null mutant
Boominathan, A., Vanhoozer, S., Basisty, N., Powers, K., Crampton, A. L., Wang, X., Friedricks, N., Schilling, B., Brand, M. D., & O'Connor, M. S. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw756 · Cited by 27
Dunn, D. A., & Pinkert, C. A. (2012) · Journal of Biomedicine and Biotechnology · doi:10.1155/2012/541245 · Cited by 25
Exogenous expression of ATP8, a mitochondrial encoded protein, from the nucleus in vivo
Begelman, D. V., Dixit, B., Truong, C., King, C. D., Watson, M. A., Schilling, B., Brand, M. D., & Boominathan, A. (2024) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2024.101372 · Cited by 5
Metadata
- Authors
- Cwerman‐Thibault, H., Sahel, J., & Corral‐Debrinski, M.
- Venue
- Journal of Inherited Metabolic Disease
- Publisher
- Wiley
- Published
- 2010-06-23
- Volume
- 34
- Issue
- 2
- Pages
- 327-344
- ISSN
- 0141-8955 (ISSN-L)
- 1573-2665
- OpenAlex
- W2015664814
- Cited by
- 36
- References
- 19
- FWCI
- 1.89
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.